Table 1.
PSA levels by study population characteristics
| Sample Size | Median ng/ml tPSA (95% CI) | Median ng/ml fPSA (95% CI) | Median %fPSA Less Than 25% (95% CI) | |
|---|---|---|---|---|
| Total | 3,820 | 0.90 (0.81–0.90) | 0.26 (0.25–0.28) | 34.2 (31.6–36.9) |
| Age: | ||||
| 40–49 | 1,115 | 0.70 (0.70–0.75) | 0.21 (0.20–0.23) | 31.8 (28.5–35.3) |
| 50–59 | 827 | 0.90 (0.80–0.95) | 0.26 (0.24–0.27) | 35.3 (31.9–38.9) |
| 60–69 | 840 | 1.20 (1.08–1.35) | 0.33 (0.31–0.36) | 39.2 (34.8–43.8) |
| 70+ | 1,038 | 1.70 (1.58–1.90) | 0.48 (0.45–0.52) | 32.8 (28.2–37.9) |
| Race/ethnicity: | ||||
| NonHispanic white | 2,205 | 0.90 (0.80–0.94) | 0.27 (0.25–0.28) | 33.6 (30.9–36.5) |
| NonHispanic black | 709 | 0.90 (0.80–1.00) | 0.27 (0.25–0.30) | 34.0 (29.9–38.4) |
| Mexican-American | 695 | 0.90 (0.80–0.97) | 0.24 (0.22–0.25) | 40.1 (34.8–45.7) |
| Other | 211 | 0.80 (0.70–1.00) | 0.24 (0.20–0.28) | 36.7 (26.3–48.4) |
| Family history of prostate Ca:* | ||||
| No | 2,073 | 0.85 (0.80–0.90) | 0.26 (0.25–0.27) | 31.7 (28.8–34.7) |
| Yes | 199 | 0.97 (0.73–1.30) | 0.31 (0.25–0.35) | 31.0 (23.9–39.1) |
| Smoking status: | ||||
| Current smoker | 1,188 | 0.80 (0.80–0.90) | 0.24 (0.23–0.25) | 38.3 (34.6–42.1) |
| Former smoker | 1,359 | 0.95 (0.83–1.01) | 0.28 (0.27–0.30) | 31.3 (27.3–35.6) |
| Never smoker | 1,270 | 0.90 (0.80–0.94) | 0.27 (0.25–0.29) | 33.1 (29.4–37.0) |
| BMI (kg/m2): | ||||
| Normal (less than 25) | 905 | 1.00 (0.90–1.10) | 0.30 (0.28–0.33) | 35.2 (31.2–39.3) |
| Overweight (25–less than 30) | 1,621 | 0.90 (0.80–0.95) | 0.27 (0.25–0.28) | 33.5 (30.2–36.9) |
| Obese (30+) | 1,187 | 0.80 (0.76–0.89) | 0.25 (0.23–0.25) | 34.3 (30.2–38.6) |
| Diabetes: | ||||
| No | 3,253 | 0.90 (0.84–0.91) | 0.26 (0.25–0.27) | 35.0 (32.4–37.7) |
| Yes | 564 | 0.80 (0.73–0.90) | 0.27 (0.25–0.29) | 27.7 (21.7–34.5) |
| BPH: | ||||
| No | 3,114 | 0.86 (0.80–0.90) | 0.26 (0.25–0.27) | 33.7 (30.9–36.6) |
| Yes | 468 | 1.27 (1.00–1.50) | 0.35 (0.33–0.38) | 37.9 (31.5–44.9) |
| Statin use: | ||||
| No | 2,900 | 0.90 (0.80–0.90) | 0.26 (0.25–0.27) | 34.4 (31.3–37.7) |
| Yes | 769 | 0.97 (0.83–1.00) | 0.28 (0.26–0.30) | 33.6 (29.4–38.1) |
| NSAID use:† | ||||
| No | 3,419 | 0.90 (0.82–0.90) | 0.26 (0.25–0.27) | 34.2 (31.6–36.9) |
| Yes | 401 | 0.90 (0.74–1.00) | 0.28 (0.26–0.30) | 34.4 (27.8–41.7) |
| Thiazide diuretic use: | ||||
| No | 3,426 | 0.90 (0.80–0.90) | 0.26 (0.25–0.27) | 34.9 (32.2–37.6) |
| Yes | 394 | 1.00 (0.82–1.10) | 0.29 (0.25–0.33) | 27.7 (21.1–35.5) |
| Cotinine level (ng/ml): | ||||
| 10 or Less | 2,668 | 0.90 (0.86–1.00) | 0.28 (0.26–0.29) | 32.7 (29.8–35.8) |
| Greater than 10 | 1,142 | 0.80 (0.78–0.90) | 0.24 (0.22–0.25) | 37.6 (33.8–41.6) |
| C-reactive protein (mg/dl): | ||||
| Less than 1.0 | 3,499 | 0.90 (0.80–0.90) | 0.26 (0.25–0.27) | 33.6 (31.0–36.3) |
| 1.0–3.0 | 261 | 0.84 (0.73–1.15) | 0.25 (0.22–0.31) | 40.1 (31.9–48.9) |
| Greater than 3.0 | 60 | 1.16 (1.00–1.40) | 0.30 (0.21–0.40) | 53.7 (36.3–70.3) |
*
Only available for the NHANES 2003–2006.
†
Prescription only.